Melanoma is deadly, physically impairing, and has ongoing treatment deficiencies. Current
treatment regimens include surgery, targeted kinase inhibitors, immunotherapy, and …

The establishment of genomics in health care systems has been occurring for the past
decade. It is recognised that implementing genomics within a health service is challenging …

Melanoma is a malignant tumor with aggressive behavior. Vemurafenib, a BRAF inhibitor, is
clinically used in melanoma, but resistance to melanoma cytotoxic therapies is associated …

Abstract The MITF (E318K) variant confers moderate risk for cutaneous melanoma. While
there are small studies suggesting that this risk is associated with other malignancies (eg …

Background Cutaneous melanoma survivors are at increased risk of a second primary
melanoma. Valid estimates facilitate counseling on recommended surveillance after a …

Background Over the past decades, many regions have experienced a steady increase in
the incidence of cutaneous melanoma. Here, we report on incidence trends for subsequent …

Abstract Background: Inherited pathogenic variants (PVs) in the CDKN2A gene are among
the strongest known risk factors for cutaneous melanoma. Carriers are at high risks to …

Motivation Analyzing genetic data to identify markers and construct predictive models is of
great interest in biomedical research. However, limited by cost and sample availability …

Background Nodular melanoma (NM) is a challenge to diagnose early due to its rapid
growth and more atypical clinical presentation, making it the largest contributor to melanoma …

Background Compared with the general population, people with a previous melanoma are
at increased risk of developing another primary melanoma. Understanding the risk factors …